Coya Therapeutics (NASDAQ:COYA) Receives "Buy" Rating from D. Boral Capital

D. Boral Capital restated their buy rating on shares of Coya Therapeutics (NASDAQ:COYA - Free Report) in a research report report published on Wednesday morning,Benzinga reports. They currently have a $15.00 price objective on the stock.

Several other research firms have also recently issued reports on COYA. Chardan Capital reaffirmed a "buy" rating and issued a $14.00 price objective on shares of Coya Therapeutics in a research report on Thursday, November 7th. HC Wainwright reaffirmed a "buy" rating and set a $18.00 price target on shares of Coya Therapeutics in a report on Monday, November 11th.

Coya Therapeutics Stock Performance

Shares of COYA traded down $0.40 during trading hours on Wednesday, hitting $5.21. The company had a trading volume of 82,933 shares, compared to its average volume of 71,752. Coya Therapeutics has a 52-week low of $4.75 and a 52-week high of $10.69. The firm has a fifty day moving average price of $7.00 and a 200-day moving average price of $6.65. The stock has a market capitalization of $87.04 million, a price-to-earnings ratio of -8.02 and a beta of 0.26.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) last issued its earnings results on Wednesday, November 6th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.15. Research analysts anticipate that Coya Therapeutics will post -1.15 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Arun Swaminathan purchased 5,000 shares of the stock in a transaction dated Monday, November 11th. The shares were purchased at an average cost of $7.34 per share, with a total value of $36,700.00. Following the acquisition, the chief executive officer now directly owns 5,000 shares of the company's stock, valued at $36,700. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In the last quarter, insiders purchased 9,510 shares of company stock valued at $69,615. Company insiders own 12.00% of the company's stock.

Institutional Trading of Coya Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC grew its stake in shares of Coya Therapeutics by 3.3% during the 3rd quarter. Geode Capital Management LLC now owns 142,309 shares of the company's stock valued at $918,000 after purchasing an additional 4,485 shares during the period. GHP Investment Advisors Inc. purchased a new position in shares of Coya Therapeutics in the third quarter worth approximately $169,000. Renaissance Technologies LLC bought a new stake in Coya Therapeutics during the second quarter valued at approximately $101,000. Finally, Gilbert & Cook Inc. purchased a new stake in Coya Therapeutics during the second quarter valued at approximately $61,000. Hedge funds and other institutional investors own 39.75% of the company's stock.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.